Drug Approval | April 02, 2024
AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
Application based on results from the TROPION-Breast01 Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
WINREVAIR is a breakthrough biologic for this rare, progressive disease
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
To accelerate the development of next-generation radioconjugates to treat cancer
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
It is the first autotaxin inhibitor to be investigated in cancer patients
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Subscribe To Our Newsletter & Stay Updated
